Exocrine Pancreatic Insufficiency Drug Products; Extension to Obtain Marketing Approval

Summary

The Food and Drug Administration (FDA) is extending the enforcement discretion for exocrine pancreatic insufficiency drug products until April 28, 2010, allowing manufacturers with active INDs and NDA submissions to continue selling these products. This extension aims to ensure the continued availability of these products during the time needed to obtain marketing approval.